Kiadis: Adjunctive HSCT therapies looking for solid ground
Although the medical need remains high to improve clinical outcomes for hematopoietic stem cell transplantations (HSCT), sentiment around adjunctive HSCT therapies is at a low after MolMed’s failed commercialisation of Zalmoxis and associated phase III trial. In this note, we outline Zalmoxis’ trajectory, compare to Kiadis’ ATIR101 and assess possible scenario’s going forward for Kiadis.Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Co.' lead product ATIR101 is being tested using a single-dose regimen in patients with blood cancer who have not found a matching donor and where a partially matched (haploidentical) family member is used as donor for HSCT.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.